Last month Medtronic agreed to pay close to $800 million for Chinese orthopedics implant maker China Kanghui Holdings. To be sure, the purchase of Kanghui secures Medtronic’s footing in China, one of the fastest growing health care economies in the world. In addition, it likely will help Medtronic close in on its goal of bringing in 20% of its revenue from emerging markets.

China Kanghui has emerged as one of the leaders in China’s orthopedics industry, building a business first on trauma and, more recently, spine. Now, with a pending move into reconstruction, the company is looking to other emerging markets, and eventually the US and Europe.

The Scientific Committee on Consumer Safety will consider available safety data for prostaglandin analogs isopropyl cloprostenate, ethyl tafluprostamide and others with known use in eyelash-growth cosmetic products in the EU. Currently, the substances are not restricted in cosmetic products.